M., Kopp, J
October 2024 : Acadia Pharmaceuticals received approval from Health Canada for DAYBUE (trofinetide) for the treatment of Rett syndrome, making it the first and only drug approved for this rare neurodevelopmental disorder in the country
The common side effects of Acamprosate include diarrhea, nausea, and insomnia, while rare but severe side effects may involve depression, allergic reactions, or kidney-related complications, requiring close monitoring
Results can vary based on dosage, consistency, overall health, and whether the peptide is being used for recovery, inflammation, or other wellness goals
This supplementation enhances sperm parameters, regulates hormone levels, reduces ROS levels, and subsequently improves fertility rates
Decisions about continuing or stopping treatment are made with a licensed provider and guided by safety and long-term health outcomes